11 research outputs found
Computed microtomography visualization and quantification of mouse ischemic brain lesion by nonionic radio contrast agents
Aim To explore the possibility of brain imaging by microcomputed
tomography (microCT) using x-ray contrasting
methods to visualize mouse brain ischemic lesions after
middle cerebral artery occlusion (MCAO).
Methods Isolated brains were immersed in ionic or nonionic
radio contrast agent (RCA) for 5 days and subsequently
scanned using microCT scanner. To verify whether
ex-vivo microCT brain images can be used to characterize
ischemic lesions, they were compared to Nissl stained
serial histological sections of the same brains. To verify if
brains immersed in RCA may be used afterwards for other
methods, subsequent immunofluorescent labeling with
anti-NeuN was performed.
Results Nonionic RCA showed better gray to white matter
contrast in the brain, and therefore was selected for further
studies. MicroCT measurement of ischemic lesion size and
cerebral edema significantly correlated with the values determined
by Nissl staining (ischemic lesion size: P=0.0005;
cerebral edema: P=0.0002). Brain immersion in nonionic
RCA did not affect subsequent immunofluorescent analysis
and NeuN immunoreactivity.
Conclusion MicroCT method was proven to be suitable
for delineation of the ischemic lesion from the non-infarcted
tissue, and quantification of lesion volume and cerebral
edema
Glowbrain ā an in vitro and in vivo platform for studying the regenerative potential of the murine neural stem cell applications in repair of ischemic brain injury
The effect of natriuretic peptide on the bradykinin signaling pathway after ischemic injury in the mouse brain
ZaÄepljenje moždanih arterija dovodi do moždanog udara te posljediÄno do moždanog edema
koji pridonosi poveÄanju ishemijske ozljede. Kako je bradikinin izravni uzroÄnik moždanog
edema te natriuretski peptidi smanjuju moždani edem nakon moždanog udara joŔ uvijek
nepoznatim mehanizmom, cilj ovog istraživanja bio je razjasniti moguÄi mehanizam
djelovanja natriuretskih peptida na signalni sustav bradikinina te uÄinak njihovog
meÄudjelovanja na dogaÄaje koji slijede nakon ishemijske ozljede mozga. HEK-293 stanice
su koriÅ”tene kao staniÄni model jer smo pokazali, koristeÄi RT-PCR, postojanje
bradikininskih receptora tipa 1 i 2, gvanilat ciklaze A i B te natriuretskog receptora tipa C.
Mjerenjem membranskih potencijala i unutarstaniÄne koncentracije kalcija HEK-293 stanica
pokazali smo da natriuretski peptidi, agonisti gvanilat ciklaze-A (atrijski natriuretski peptid,
moždani natriuretski peptid, urodilatin), ali ne i gunailat ciklaze-B (C-tip natriuretski peptid)
inhibiraju bradikininski signalni put nakon aktivacije njegovog receptora tipa 2. U in vivo
pokusima na miŔjem modelu moždanog udara pokazali smo da i.v. primjena urodilatina
sprjeÄava nastanak ishemijske lezije mozga te posljediÄnog moždanog edema koje smo
odreÄivali mjerenjem stupnja neuroloÅ”kog oÅ”teÄenja, oslikavanjem mozgova
mikrokompjuteriziranom tomografijom, serijskim rezovima mozgova histoloŔki bojenim po
Nisslu te odreÄivanjem sadržaja vode u mozgu. Rezultati ovog istraživanja po prvi puta
pokazuju postojanje prirodnog antagonista bradikininskog receptora tipa 2 te moguÄu
primjenu natriuretskih peptida u lijeÄenju moždanog udara.Occlusion of the cerebral arteries leads to stroke and its consequence brain edema which
further increases the brain damage. The aim of this research was clarifying the possible
mechanisms of action of natriuretic peptides on bradykinin signaling, and their interactive
effects after ischemic brain injury, since bradykinin is involved in the formation of cerebral
edema and natriuretic peptides decrease brain edema via still unknown manner. HEK-293
cells were used as a model since using RT-PCR we proved the existence of bradykinin
receptors type 1 and 2, guanylyl cyclase A and B, and natriuretic receptor type C. Measuring
membrane potentials and intercellular calcium concentrations in HEK-293 cells we showed
that natriuretic peptides, guanylyl cyclase A agonists (atrial natriuretic peptide, brain
natriuretic peptide, urodilatin), excluding the guanylil cyclase B (C-type natriuretic peptide)
inhibited the bradykinin signaling pathway after activation of bradykinin receptor type 2. The
in vivo experiments on the animal model showed that urodilatin inhibited the formation of the
ischemic lesion and brain edema which was measured by neurological scoring, visualization
with microcomputerized tomography, serial Nissl stained sections and brain water content.
The results of this research show for the first time the existence of a natural antagonist of the
bradykinin type 2 receptor, and the possible use of natriuretic peptides in treatment of stroke
The effect of natriuretic peptide on the bradykinin signaling pathway after ischemic injury in the mouse brain
ZaÄepljenje moždanih arterija dovodi do moždanog udara te posljediÄno do moždanog edema
koji pridonosi poveÄanju ishemijske ozljede. Kako je bradikinin izravni uzroÄnik moždanog
edema te natriuretski peptidi smanjuju moždani edem nakon moždanog udara joŔ uvijek
nepoznatim mehanizmom, cilj ovog istraživanja bio je razjasniti moguÄi mehanizam
djelovanja natriuretskih peptida na signalni sustav bradikinina te uÄinak njihovog
meÄudjelovanja na dogaÄaje koji slijede nakon ishemijske ozljede mozga. HEK-293 stanice
su koriÅ”tene kao staniÄni model jer smo pokazali, koristeÄi RT-PCR, postojanje
bradikininskih receptora tipa 1 i 2, gvanilat ciklaze A i B te natriuretskog receptora tipa C.
Mjerenjem membranskih potencijala i unutarstaniÄne koncentracije kalcija HEK-293 stanica
pokazali smo da natriuretski peptidi, agonisti gvanilat ciklaze-A (atrijski natriuretski peptid,
moždani natriuretski peptid, urodilatin), ali ne i gunailat ciklaze-B (C-tip natriuretski peptid)
inhibiraju bradikininski signalni put nakon aktivacije njegovog receptora tipa 2. U in vivo
pokusima na miŔjem modelu moždanog udara pokazali smo da i.v. primjena urodilatina
sprjeÄava nastanak ishemijske lezije mozga te posljediÄnog moždanog edema koje smo
odreÄivali mjerenjem stupnja neuroloÅ”kog oÅ”teÄenja, oslikavanjem mozgova
mikrokompjuteriziranom tomografijom, serijskim rezovima mozgova histoloŔki bojenim po
Nisslu te odreÄivanjem sadržaja vode u mozgu. Rezultati ovog istraživanja po prvi puta
pokazuju postojanje prirodnog antagonista bradikininskog receptora tipa 2 te moguÄu
primjenu natriuretskih peptida u lijeÄenju moždanog udara.Occlusion of the cerebral arteries leads to stroke and its consequence brain edema which
further increases the brain damage. The aim of this research was clarifying the possible
mechanisms of action of natriuretic peptides on bradykinin signaling, and their interactive
effects after ischemic brain injury, since bradykinin is involved in the formation of cerebral
edema and natriuretic peptides decrease brain edema via still unknown manner. HEK-293
cells were used as a model since using RT-PCR we proved the existence of bradykinin
receptors type 1 and 2, guanylyl cyclase A and B, and natriuretic receptor type C. Measuring
membrane potentials and intercellular calcium concentrations in HEK-293 cells we showed
that natriuretic peptides, guanylyl cyclase A agonists (atrial natriuretic peptide, brain
natriuretic peptide, urodilatin), excluding the guanylil cyclase B (C-type natriuretic peptide)
inhibited the bradykinin signaling pathway after activation of bradykinin receptor type 2. The
in vivo experiments on the animal model showed that urodilatin inhibited the formation of the
ischemic lesion and brain edema which was measured by neurological scoring, visualization
with microcomputerized tomography, serial Nissl stained sections and brain water content.
The results of this research show for the first time the existence of a natural antagonist of the
bradykinin type 2 receptor, and the possible use of natriuretic peptides in treatment of stroke
The effect of natriuretic peptide on the bradykinin signaling pathway after ischemic injury in the mouse brain
ZaÄepljenje moždanih arterija dovodi do moždanog udara te posljediÄno do moždanog edema
koji pridonosi poveÄanju ishemijske ozljede. Kako je bradikinin izravni uzroÄnik moždanog
edema te natriuretski peptidi smanjuju moždani edem nakon moždanog udara joŔ uvijek
nepoznatim mehanizmom, cilj ovog istraživanja bio je razjasniti moguÄi mehanizam
djelovanja natriuretskih peptida na signalni sustav bradikinina te uÄinak njihovog
meÄudjelovanja na dogaÄaje koji slijede nakon ishemijske ozljede mozga. HEK-293 stanice
su koriÅ”tene kao staniÄni model jer smo pokazali, koristeÄi RT-PCR, postojanje
bradikininskih receptora tipa 1 i 2, gvanilat ciklaze A i B te natriuretskog receptora tipa C.
Mjerenjem membranskih potencijala i unutarstaniÄne koncentracije kalcija HEK-293 stanica
pokazali smo da natriuretski peptidi, agonisti gvanilat ciklaze-A (atrijski natriuretski peptid,
moždani natriuretski peptid, urodilatin), ali ne i gunailat ciklaze-B (C-tip natriuretski peptid)
inhibiraju bradikininski signalni put nakon aktivacije njegovog receptora tipa 2. U in vivo
pokusima na miŔjem modelu moždanog udara pokazali smo da i.v. primjena urodilatina
sprjeÄava nastanak ishemijske lezije mozga te posljediÄnog moždanog edema koje smo
odreÄivali mjerenjem stupnja neuroloÅ”kog oÅ”teÄenja, oslikavanjem mozgova
mikrokompjuteriziranom tomografijom, serijskim rezovima mozgova histoloŔki bojenim po
Nisslu te odreÄivanjem sadržaja vode u mozgu. Rezultati ovog istraživanja po prvi puta
pokazuju postojanje prirodnog antagonista bradikininskog receptora tipa 2 te moguÄu
primjenu natriuretskih peptida u lijeÄenju moždanog udara.Occlusion of the cerebral arteries leads to stroke and its consequence brain edema which
further increases the brain damage. The aim of this research was clarifying the possible
mechanisms of action of natriuretic peptides on bradykinin signaling, and their interactive
effects after ischemic brain injury, since bradykinin is involved in the formation of cerebral
edema and natriuretic peptides decrease brain edema via still unknown manner. HEK-293
cells were used as a model since using RT-PCR we proved the existence of bradykinin
receptors type 1 and 2, guanylyl cyclase A and B, and natriuretic receptor type C. Measuring
membrane potentials and intercellular calcium concentrations in HEK-293 cells we showed
that natriuretic peptides, guanylyl cyclase A agonists (atrial natriuretic peptide, brain
natriuretic peptide, urodilatin), excluding the guanylil cyclase B (C-type natriuretic peptide)
inhibited the bradykinin signaling pathway after activation of bradykinin receptor type 2. The
in vivo experiments on the animal model showed that urodilatin inhibited the formation of the
ischemic lesion and brain edema which was measured by neurological scoring, visualization
with microcomputerized tomography, serial Nissl stained sections and brain water content.
The results of this research show for the first time the existence of a natural antagonist of the
bradykinin type 2 receptor, and the possible use of natriuretic peptides in treatment of stroke
UÄinak natriuretskih peptida na signalni put bradikinina nakon ishemijskog oÅ”teÄenja miÅ”jeg mozga [The effect of natriuretic peptide on the bradykinin signaling pathway after ischemic injury in the mouse brain]
Occlusion of the cerebral arteries leads to stroke and its consequence brain edema which
further increases the brain damage. The aim of this research was clarifying the possible
mechanisms of action of natriuretic peptides on bradykinin signaling, and their interactive
effects after ischemic brain injury, since bradykinin is involved in the formation of cerebral
edema and natriuretic peptides decrease brain edema via still unknown manner. HEK-293
cells were used as a model since using RT-PCR we proved the existence of bradykinin
receptors type 1 and 2, guanylyl cyclase A and B, and natriuretic receptor type C. Measuring
membrane potentials and intercellular calcium concentrations in HEK-293 cells we showed
that natriuretic peptides, guanylyl cyclase A agonists (atrial natriuretic peptide, brain
natriuretic peptide, urodilatin), excluding the guanylil cyclase B (C-type natriuretic peptide)
inhibited the bradykinin signaling pathway after activation of bradykinin receptor type 2. The
in vivo experiments on the animal model showed that urodilatin inhibited the formation of the
ischemic lesion and brain edema which was measured by neurological scoring, visualization
with microcomputerized tomography, serial Nissl stained sections and brain water content.
The results of this research show for the first time the existence of a natural antagonist of the
bradykinin type 2 receptor, and the possible use of natriuretic peptides in treatment of stroke
KrĆ¼ppel-like transcription factor 8 (Klf8) is expressed and active in the neurons of the mouse brain
KrĆ¼ppel-like transcription factor 8 (KLF8) is a transcription factor suggested to be involved in various cellular events, including malignant cell transformation, still its expression in the adult rodent brain remained unknown. To analyze Klf8 in the mouse brain and to identify cell types expressing it, a specific transgenic Klf8(Gt1Gaj) mouse was used. The resulting Klf8 gene-driven Ī²-galactosidase activity was visualized by X-gal histochemical staining of the brain sections. The obtained results were complemented by in situ RNA hybridization and immunohistochemistry. Klf8 was highly expressed throughout the adult mouse brain gray matter including the cerebral cortex, hippocampus, olfactory bulb, hypothalamus, pallidum, and striatum, but not in the cerebellum. Immunofluorescent double-labeling revealed that KLF8-immunoreactive cells were neurons, and the staining was located in their nucleus. This was the first study showing that Klf8 was highly expressed in various regions of the mouse brain and in particular in the neurons, where it was localized in the cell nuclei
Role of uroguanylin's signalling pathway in the development of ischaemic stroke
Stroke is one of the leading causes of mortality and disability worldwide. By affecting bradykinin function, activation of guanylate cyclase (GC)-A has been shown to have a neuroprotective effect after ischaemic stroke, whereas the same has not been confirmed for GC-B; therefore, we aimed to determine the possible role of GC-C and its agonist, uroguanylin (UGN), in the development of stroke. In this study, middle cerebral artery occlusion (MCAO) was performed on wild-type (WT), GC-C KO and UGN KO mice. MR images were acquired before and 24 h after MCAO. On brain slices 48 h after MCAO, the Ca2+ response to UGN stimulation was recorded. Our results showed that the absence of GC-C in GC-C KO mice resulted in the development of smaller ischaemic lesions compared with WT littermates, which is an opposite effect compared with the effects of GC-A agonists on brain lesions. WT and UGN KO animals showed a stronger Ca2+ response upon UGN stimulation in astrocytes of the peri-ischaemic cerebral cortex compared with the same cortical region of the unaffected contralateral hemisphere. This stronger activation was not observed in GC-C KO animals, which may be the reason for smaller lesion development in GC-C KO mice. The reason why GC-C might affect Ca2+ signalling in peri-ischaemic astrocytes is that GC-C is expressed in these cells after MCAO, whereas under normoxic conditions, it is expressed mainly in cortical neurons. Stronger activation of the Ca2+ -dependent signalling pathway could lead to the stronger activation of the Na+ /H+ exchanger, tissue acidification and neuronal death
Improved biocompatibility and efficient labeling of neural stem cells with poly(L-lysine)-coated maghemite nanoparticles
Background: Cell tracking is a powerful tool to understand cellular migration, dynamics, homing and function of stem cell transplants. Nanoparticles represent possible stem cell tracers, but they differ in cellular uptake and side effects. Their properties can be modified by coating with different biocompatible polymers. To test if a coating polymer, poly(L-lysine), can improve the biocompatibility of nanoparticles applied to neural stem cells, poly(L-lysine)-coated maghemite nanoparticles were prepared and characterized. We evaluated their cellular uptake, the mechanism of internalization, cytotoxicity, viability and proliferation of neural stem cells, and compared them to the commercially available dextran-coated nanomagĀ®-D-spio nanoparticles.Results: Light microscopy of Prussian blue staining revealed a concentration-dependent intracellular uptake of iron oxide in neural stem cells. The methyl thiazolyl tetrazolium assay and the calcein acetoxymethyl ester/propidium iodide assay demonstrated that poly(L-lysine)-coated maghemite nanoparticles scored better than nanomagĀ®-D-spio in cell labeling efficiency, viability and proliferation of neural stem cells. Cytochalasine D blocked the cellular uptake of nanoparticles indicating an actin-dependent process, such as macropinocytosis, to be the internalization mechanism for both nanoparticle types. Finally, immunocytochemistry analysis of neural stem cells after treatment with poly(L-lysine)-coated maghemite and nanomagĀ®-D-spio nanoparticles showed that they preserve their identity as neural stem cells and their potential to differentiate into all three major neural cell types (neurons, astrocytes and oligodendrocytes).Conclusion: Improved biocompatibility and efficient cell labeling makes poly(L-lysine)-coated maghemite nanoparticles appropriate candidates for future neural stem cell in vivo tracking studies